Cargando…

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?

Cannabidiol (CBD)-containing products are widely marketed as over the counter products, mostly as food supplements. Adverse effects reported in anecdotal consumer reports or during clinical studies were first assumed to be due to acid-catalysed cyclization of CBD to psychotropic Δ (9)tetrahydrocanna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lachenmeier, Dirk W., Habel, Stephanie, Fischer, Berit, Herbi, Frauke, Zerbe, Yvonne, Bock, Verena, Rajcic de Rezende, Tabata, Walch, Stephan G., Sproll, Constanze
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029751/ https://www.ncbi.nlm.nih.gov/pubmed/32117565 http://dx.doi.org/10.12688/f1000research.19931.6

Ejemplares similares

Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
por: Golombek, Patricia, et al.
Publicado: (2020)

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014)

The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice
por: Eitan, Adi, et al.
Publicado: (2023)

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
por: Arkell, Thomas R., et al.
Publicado: (2019)

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
por: Hutten, Nadia R. P. W., et al.
Publicado: (2022)

Comment on Lachenmeier et al (2020) “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”: disputation on various points in the publication
por: Kruse, Daniel, et al.
Publicado: (2020)

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
por: Meyer, Thomas, et al.
Publicado: (2019)

Proteome-Wide Profiling Using Sample Multiplexing of a Human Cell Line Treated with Cannabidiol (CBD) and Tetrahydrocannabinol (THC)
por: Abyadeh, Morteza, et al.
Publicado: (2023)

Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (∆(9)-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation
por: Ahmed, Kazi T., et al.
Publicado: (2018)

Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)—A Pilot Study
por: Rudroff, Thorsten, et al.
Publicado: (2022)

A Critical Review of the Role of the Cannabinoid Compounds Δ(9)-Tetrahydrocannabinol (Δ(9)-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment
por: Jones, Éamon, et al.
Publicado: (2020)

Study of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) extraction FROM dried oral fluid spots (DOFS) and LC–MS/MS detection
por: Gorziza, Roberta, et al.
Publicado: (2021)

Absence of Relevant Thermal Conversion of Cannabidiol to Tetrahydrocannabinol in E-Cigarette Vapor and Low-Tetrahydrocannabinol Cannabis Smoke
por: Hindelang, Pascal, et al.
Publicado: (2022)

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination
por: Linher-Melville, Katja, et al.
Publicado: (2020)

Efficacy of Δ(9) -Tetrahydrocannabinol (THC) Alone or in Combination With a 1:1 Ratio of Cannabidiol (CBD) in Reversing the Spatial Learning Deficits in Old Mice
por: Nidadavolu, Prakash, et al.
Publicado: (2021)

Time Trends of Tetrahydrocannabinol (THC) in a 2008–2021 German National Survey of Hemp Food Products
por: Dräger, Hannah, et al.
Publicado: (2022)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
por: Stauch, Chris M., et al.
Publicado: (2020)

Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model
por: Yekhtin, Zhanna, et al.
Publicado: (2022)

Pilot clinical and pharmacokinetic study of Δ(9)-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain
por: Clarke, Stephen, et al.
Publicado: (2022)

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
por: Suraev, Anastasia, et al.
Publicado: (2020)

O006 Acute effects of combined cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density EEG
por: Suraev, A, et al.
Publicado: (2022)

Evidence for adverse effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association
por: Lachenmeier, Dirk W., et al.
Publicado: (2021)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, on Tendon to Tendon Healing in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
por: Stauch, Chris, et al.
Publicado: (2020)

CBD, a precursor of THC in e-cigarettes
por: Czégény, Zsuzsanna, et al.
Publicado: (2021)

Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats
por: Gabaglio, Marina, et al.
Publicado: (2021)

Cannabidiol (CBD) in Cancer Management
por: O’Brien, Kylie
Publicado: (2022)

The Impact of THC and CBD in Schizophrenia: A Systematic Review
por: Ahmed, Saeed, et al.
Publicado: (2021)

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
por: Hardy, Janet, et al.
Publicado: (2020)

THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
por: Pintori, Nicholas, et al.
Publicado: (2023)

Towards Better Delivery of Cannabidiol (CBD)
por: Millar, Sophie Anne, et al.
Publicado: (2020)

Cannabidiol (CBD) and Insomnia : Literature review
por: Gutierrez Higueras, T., et al.
Publicado: (2022)

The use of cannabidiol (CBD) as an analgesic component
por: Petersen, Kristian Kjær-Staal, et al.
Publicado: (2023)

Acute human exposure assessment to tetrahydrocannabinol (Δ(9)‐THC)
por: Arcella, Davide, et al.
Publicado: (2020)

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
por: Englund, Amir, et al.
Publicado: (2022)

Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD)
por: Nasrin, Shamema, et al.
Publicado: (2023)

A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC
por: Kim, Seok Hee, et al.
Publicado: (2019)

Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot
por: Pennypacker, Sarah D., et al.
Publicado: (2022)

Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging
por: Gilman, Jodi M., et al.
Publicado: (2022)

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)
por: Boehnke, Kevin F., et al.
Publicado: (2022)

The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne
por: Peyravian, Nadia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7b9lud5hugt197052ebrljqth4